Anavex Life Sciences Corp (AVXL)

[kevindenver]

No company goes this quiet for no reason.

Unless S1R and muscarinic modulation proves out to be a failure, of which I don't think that's the case. I base that opinion on the growing body of S1R academic research and not from Anavex exclusively.

Heck a friend passed me this random academic S1R tidbit this afternoon:

The Neuroprotective Effect of Activation of Sigma-1 Receptor on Neural Injury by Optic Nerve Crush
https://pubmed.ncbi.nlm.nih.gov/37669061/

Of course it's jus a rat study, but it's all part of a larger pattern.

I think it will be in the $8B -$12B range

is fair, but that valuation will not be upfront, but instead be part of a Contingent Value Rights deal.